| |
|
|
-
| Padiatr Padol 1993;28(5):133-6 |
|
Childhood obesity treatment:
double blinded trial on dietary fibres (glucomannan) versus
placebo.
Vido L, Facchin P, Antonello I, Gobber D, Rigon F.
Department of Pediatrics, University of Padova, Italy.
Dietary fibres are frequently used for the treatment of paediatric
obesity. The aim of this clinical trial is to evaluate the efficacy
of glucomannan in the child obesity management. This experimental
design was double blinded with a block randomisation, alpha
= 0.05, beta = 0.2 and delta = 50%. The study involved 60 children
under 15 years of age (mean age 11.2 years, mean overweight
46%), 30 of them under glucomannan treatment (1 g twice a day
for two months) and 30 under placebo and the same schedule.
The drug and the placebo were indistinguishable both for the
family and the physician. During the two months study period
the children followed a normocaloric diet evaluated every two
weeks by a dietetic record book. At the beginning of the study
the drug and the placebo groups were comparable in regards to
anthropometric data. At the end, the mean overweight of the
drug group was decreased from 49.5% to 41% and that of the placebo
group from 43.9% to 41.7%. Both decreases were significant (p
< 0.01), but no significant difference was observed between
the drug and the placebo groups. The only significant difference
concerned the lipid metabolism. The children under glucomannan
treatment manifested a significant decrease of alpha-lipoprotein
and an increase of pre-beta-lipoprotein and triglycerides; the
children under placebo manifested only a decrease of triglycerides
and apo beta-lipoprotein. We suggest that this metabolic alteration
may derive from a primary decrease of alpha-lipoprotein, most
likely because of an inadequate water intake.(ABSTRACT TRUNCATED
AT 250 WORDS)
Publication Types:
- Clinical Trial
- Randomized Controlled Trial
|
|
|